Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
21.87
+1.64 (8.11%)
Sep 15, 2025, 3:45 PM EDT - Market open
Zenas BioPharma Revenue
Zenas BioPharma had revenue of $15.00M in the twelve months ending June 30, 2025, down -70.00% year-over-year. In the year 2024, Zenas BioPharma had annual revenue of $5.00M, down -90.00%.
Revenue (ttm)
$15.00M
Revenue Growth
-70.00%
P/S Ratio
44.96
Revenue / Employee
$115,385
Employees
130
Market Cap
920.95M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
Dec 31, 2023 | 50.00M | - | - |
Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZBIO News
- 13 days ago - Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - GlobeNewsWire
- 20 days ago - Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 4 weeks ago - Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 7 weeks ago - Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS - Seeking Alpha
- 3 months ago - Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO - PRNewsWire
- 3 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - PRNewsWire
- 3 months ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - GlobeNewsWire